# Clinical Trials Data KIT - Document 62

# A Study of Sunitinib In Young Patients With Advanced Gastrointestinal Stromal Tumor

## Clinical Trial: https://clinicaltrials.gov/study/NCT01396148

"eligibilityCriteria": "Inclusion Criteria:\n\n\* Histological diagnosis of GIST.\n\* Patients must have demonstrated either disease progression or intolerance to imatinib mesylate, have non-mutant Stem Cell Factor Receptor gene (KIT) GIST, or cannot obtain imatinib in their country\n\* Measurable by Response Evaluation Criterion in Solid Tumors (RECIST) or evaluable disease.\n\nExclusion Criteria:\n\n\* Current treatment with another investigational agent.\n\* Prior sunitinib treatment.\n\* Prior therapy with known risk for cardiovascular complications.",  
 "healthyVolunteers": false,  
 "sex": "ALL",  
 "minimumAge": "6 Years",  
"stdAges": [  
"CHILD",  
"ADULT"  
]

Question:  
Based on the following clinical trial information, would a patient with a KIT gene mutation be eligible for the clinical trial?

Answer:  
No. The inclusion criteria specifically state "Patients must have... \*non-mutant Stem Cell Factor Receptor gene (KIT) GIST...". A patient \*with\* a KIT mutation would be excluded.